News summary

Combined RDW-CV and NT-proBNP for all-cause mortality prognostication in frail older cancer patients hospitalized with anticancer treatment-related cardiac dysfunction: a retrospective cohort study

Source: Frontiers - Health • Published: 17 Nov 2026, 00:00

Summarized by Masters of Longevity from Frontiers - Health.

In 399 hospitalized frail older cancer patients with CTRCD, higher RDW-CV and NT-proBNP were linked to greater all-cause mortality.

Combined RDW-CV and NT-proBNP for all-cause mortality prognostication in frail older cancer patients hospitalized with anticancer treatment-related cardiac dysfunction: a retrospective cohort study
Key Takeaways
  • Higher RDW-CV was associated with increased mortality risk.
  • Higher NT-proBNP was associated with increased mortality risk.
  • Dual-high RDW-CV and NT-proBNP had the worst prognosis.
Read the full article at Frontiers - Health ↗

Continue exploring

Recommended MoL Picks

MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.